3.4. Replacement of Subjects
Subjects will continue to be enrolled until the specified number of subjects are attained in the dose-limiting toxicity (DLT) evaluable (Phase 1) and mITT sets (Phase 2).  Subjects who have not received the target dose of axicabtagene ciloleucel will be retained in the analyses of disposition and safety, where appropriate (Section 10.5).